Canaccord Genuity Group Lowers Ionis Pharmaceuticals (NASDAQ:IONS) Price Target to $95.00

Ionis Pharmaceuticals (NASDAQ:IONS) had its target price decreased by analysts at Canaccord Genuity Group from $110.00 to $95.00 in a report issued on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. Canaccord Genuity Group’s target price points to a potential upside of 47.81% from the company’s previous close.

Other analysts have also issued research reports about the stock. Royal Bank Of Canada lifted their price objective on shares of Ionis Pharmaceuticals from $95.00 to $100.00 and gave the company an “outperform” rating in a research note on Thursday, April 30th. The Goldman Sachs Group upped their target price on shares of Ionis Pharmaceuticals from $74.00 to $75.00 and gave the company a “neutral” rating in a research note on Wednesday, June 24th. Barclays reaffirmed an “overweight” rating and set a $90.00 price target on shares of Ionis Pharmaceuticals in a report on Friday. Oppenheimer reaffirmed an “outperform” rating and set a $111.00 price target on shares of Ionis Pharmaceuticals in a research note on Thursday, April 30th. Finally, Morgan Stanley upped their price objective on shares of Ionis Pharmaceuticals from $95.00 to $130.00 and gave the company an “overweight” rating in a research report on Tuesday, April 21st. Eighteen investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Ionis Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $98.05.

Ionis Pharmaceuticals Stock Performance

Shares of NASDAQ:IONS opened at $64.27 on Friday. The company has a market cap of $10.62 billion, a P/E ratio of -31.05 and a beta of 0.36. The company has a debt-to-equity ratio of 2.75, a quick ratio of 4.09 and a current ratio of 4.10. Ionis Pharmaceuticals has a one year low of $40.03 and a one year high of $86.74. The business’s 50-day simple moving average is $76.12 and its 200 day simple moving average is $77.41.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings results on Wednesday, April 29th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.29. The firm had revenue of $246.09 million for the quarter, compared to analyst estimates of $195.56 million. Ionis Pharmaceuticals had a negative return on equity of 58.65% and a negative net margin of 30.91%.Ionis Pharmaceuticals’s revenue for the quarter was up 86.4% on a year-over-year basis. During the same period in the previous year, the company posted ($0.93) EPS. On average, sell-side analysts forecast that Ionis Pharmaceuticals will post -3.69 earnings per share for the current fiscal year.

Insider Activity at Ionis Pharmaceuticals

In other Ionis Pharmaceuticals news, CEO Brett P. Monia sold 50,000 shares of the firm’s stock in a transaction on Friday, June 26th. The shares were sold at an average price of $80.59, for a total transaction of $4,029,500.00. Following the completion of the transaction, the chief executive officer directly owned 245,571 shares of the company’s stock, valued at $19,790,566.89. This trade represents a 16.92% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Holly B. Kordasiewicz sold 60,846 shares of the company’s stock in a transaction dated Friday, June 12th. The shares were sold at an average price of $73.41, for a total transaction of $4,466,704.86. Following the completion of the sale, the executive vice president owned 22,458 shares in the company, valued at approximately $1,648,641.78. This trade represents a 73.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 244,038 shares of company stock worth $19,139,399 over the last 90 days. Company insiders own 1.81% of the company’s stock.

Institutional Trading of Ionis Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of IONS. Goldman Sachs Group Inc. increased its holdings in shares of Ionis Pharmaceuticals by 72.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 652,518 shares of the company’s stock valued at $19,686,000 after acquiring an additional 274,310 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Ionis Pharmaceuticals by 6.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 659,435 shares of the company’s stock worth $19,895,000 after purchasing an additional 39,794 shares during the period. Focus Partners Wealth increased its stake in Ionis Pharmaceuticals by 30.1% during the first quarter. Focus Partners Wealth now owns 9,832 shares of the company’s stock valued at $297,000 after purchasing an additional 2,277 shares during the last quarter. Franklin Resources Inc. bought a new stake in Ionis Pharmaceuticals during the second quarter valued at $220,000. Finally, Prudential Financial Inc. raised its holdings in shares of Ionis Pharmaceuticals by 47.8% during the second quarter. Prudential Financial Inc. now owns 9,254 shares of the company’s stock worth $341,000 after purchasing an additional 2,991 shares during the period. Institutional investors and hedge funds own 93.86% of the company’s stock.

Trending Headlines about Ionis Pharmaceuticals

Here are the key news stories impacting Ionis Pharmaceuticals this week:

• Negative Sentiment: The Phase 3 CARDIO-TTRansform trial missed its primary endpoint, hurting expectations for Ionis’ cardiovascular franchise and future revenue potential. Article Title
• Negative Sentiment: Reuters reported the AstraZeneca-Ionis heart drug failed to reduce cardiovascular deaths and recurring events, confirming the clinical setback. Article Title
• Negative Sentiment: Unusually heavy put-option activity suggests traders are positioning for more downside after the trial miss.
• Negative Sentiment: Multiple insiders sold shares under pre-arranged 10b5-1 plans, including EVP Holly Kordasiewicz, EVP C. Frank Bennett, and Director Allene M. Diaz, which may weigh on sentiment.
• Negative Sentiment: Needham cut its price target to $86 from $105, signaling a more cautious valuation outlook despite maintaining a Buy rating. Article Title
• Neutral Sentiment: Ionis raised FY2026 revenue guidance to $875 million-$900 million, which is broadly in line with consensus and helps offset some of the negative clinical news.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.